Clinical Trials Results
|
Results for the search you initiated will be displayed below.
-
Click here for details...
Cognitive impairments in cancer patients represent an important clinical problem. Studies to
date estimating prevalence of difficulties in memory, executive function, and attention
deficits have been limited by small sample sizes and many have lacked healthy control groups.
More information is needed on promising biomarkers and allelic variants that may help to
determine the etiology of impairment, identify those most vulnerable to impairment, and
develop interventions for these difficulties.
This is a longitudinal observational study of cognitive function in breast cancer and
lymphoma patients receiving chemotherapy to better understand the prevalence of cognitive
difficulties (i.e., problems with memory, executive function, and attention) in these
populations.
-
Click here for details...
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in
preventing breast cancer from coming back (relapsing) in patients with high risk, HER2
positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a
chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches
to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors,
and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some
of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in
preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared
to T-DM1 alone.
-
Click here for details...
This phase III trial compares denosumab to placebo for the prevention of breast cancer in
women with a BRCA1 germline mutation. A germline mutation is an inherited gene change which,
in the BRCA1 gene, is associated with an increased risk of breast and other cancers.
Denosumab is a monoclonal antibody that is used to treat bone loss in order to reduce the
risk of bone fractures in healthy people, and to reduce new bone growths in cancer patients
whose cancer has spread to their bones. Research has shown that denosumab may also reduce the
risk of developing breast cancer in women carrying a BRCA1 germline mutation.
-
Click here for details...
This phase III trial studies how well Mepitel Film works in reducing radiation dermatitis
(redness and peeling) in patients with breast cancer during radiation therapy after a
mastectomy. Mepitel Film may reduce the severity of skin redness and peeling in the area of
radiation.
-
Click here for details...
This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating
further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer
who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after
pre-operative chemotherapy and HER2-targeted therapy. Drugs used in chemotherapy, such as
paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading. Trastuzumab and
pertuzumab are both a form of "targeted therapy" because they work by attaching themselves to
specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When
these drugs attach to HER2 receptors, the signals that tell the cells to grow are blocked and
the tumor cell may be marked for destruction by the body's immune system. Giving paclitaxel,
trastuzumab, and pertuzumab may enable fewer chemotherapy drugs to be given without
compromising patient outcomes compared to the usual treatment.
-
Click here for details...
This phase II trial studies how well FDG-PET/CT works in assessing the response of patients
with breast cancer that has spread to the bones or mostly to the bones (bone-dominant
metastatic breast cancer). Diagnostic procedures, such as FDG-PET/CT, may work better in
measuring breast cancer activity before and after treatment compared to other standard
imaging tests.
-
Click here for details...
This phase II MATCH trial studies how well treatment that is directed by genetic testing
works in patients with solid tumors or lymphomas that have progressed following at least one
line of standard treatment or for which no agreed upon treatment approach exists. Genetic
tests look at the unique genetic material (genes) of patients' tumor cells. Patients with
genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more
from treatment which targets their tumor's particular genetic abnormality. Identifying these
genetic abnormalities first may help doctors plan better treatment for patients with solid
tumors, lymphomas, or multiple myeloma.
-
Click here for details...
The purpose of this study is to compare the effects on low risk breast cancer receiving usual
care that includes regional radiation therapy, with receiving no regional radiation therapy.
Researchers want to see if not giving this type of radiation treatment works as well at
preventing breast cancer from coming back.
-
Click here for details...
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy
results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor
recurrence (IBTR) compared to breast conservation with breast radiation and endocrine
therapy.
-
Click here for details...
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in
patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has
spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat
heart failure and high blood pressure, and it may prevent the heart from side effects of
chemotherapy.
-
Click here for details...
This randomized research trial studies how well serum tumor marker directed disease
monitoring works in monitoring patients with hormone receptor positive Her2 negative breast
cancer that has spread to other places in the body. Using markers to prompt when scans should
be ordered may be as good as the usual approach to monitoring disease.
-
Click here for details...
This phase II trial studies how well radiation therapy with or without olaparib works in
treating patients with inflammatory breast cancer. Radiation therapy uses high energy x-rays
to kill tumor cells and shrink tumors. Olaparib may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth. It is not yet known whether radiation
therapy with or without olaparib may work better in treating patients with inflammatory
breast cancer.
-
Click here for details...
This phase II trial studies the effect of sacituzumab govitecan in treating patients with
HER2-negative breast cancer that has spread to the brain (brain metastases). Sacituzumab
govitecan is a monoclonal antibody, called sacituzumab, linked to a chemotherapy drug, called
govitecan. Sacituzumab is a form of targeted therapy because it attaches to specific
molecules on the surface of cancer cells, known as Trop-2 receptors, and delivers govitecan
to kill them. Giving sacituzumab govitecan may shrink the cancer in the brain and/or extend
the time until the cancer gets worse.
|
